In optimal group, CR patients received cilostazol for 6 months in addition to dual anitplatelet therapy, whereas non-CR patients received standard dual antiplatelet therapy.

• 优化组非CR患者接受标准两联抗血小板治疗，CR患者在标准两联治疗基础上加服西洛他唑6个月。